{
    "abstract": "Vaccination is the most effective means of preventing influenza. However, the cost of producing annual seasonal influenza vaccines puts them out of reach for most developing countries. While live attenuated influenza vaccines are among the most efficacious and can be manufactured at low cost, they may require lyophilization to be stable enough for developing-country use, which adds a significant cost burden. The development of a liquid live attenuated seasonal influenza vaccine that is stable for around a year\u2014the duration of an annual influenza season\u2014would significantly improve not only the production output but also the use and accessibility of influenza vaccines in low-resource settings. In this study, potential stabilizing excipients were screened and optimized using the least stable influenza vaccine strain presently known, H1N1 (A/California/07/2009), as a model. The stability-conferring properties of the lead formulations were also tested with a Type B strain of influenza virus (B/Brisbane/60/2008). Stability was also evaluated with higher titers of influenza virus and exposure to agitation and freeze\u2013thaw stresses to further confirm the stability of the lead formulations. Through this process, we identified a liquid formulation consisting of sucrose phosphate glutamate buffer with 1% arginine and 0.5% recombinant human serum albumin that provided storage stability of one year at 2\u20138\u00a0\u00b0C for the influenza A and B strains tested.",
    "author_highlights": [
        {
            "endOffset": 23583,
            "sentence": "Multiple excipients were screened for their ability to stabilize influenza vaccine.",
            "startOffset": 23500
        },
        {
            "endOffset": 23662,
            "sentence": "Identified a liquid formulation with storage stability for one year at 2\u20138 \u00b0C.",
            "startOffset": 23584
        },
        {
            "endOffset": 23738,
            "sentence": "A stable liquid formulation may lead to wider use of influenza vaccination.",
            "startOffset": 23663
        }
    ],
    "bib_entries": {
        "bib0255": {
            "authors": [
                {
                    "first": "Kathleen M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Hohlbein"
                },
                {
                    "first": "Yuwei",
                    "initial": "Y.",
                    "last": "Zhu"
                }
            ],
            "doi": "10.1001/archpedi.156.10.986",
            "firstpage": "986",
            "issn": "10724710",
            "lastpage": "991",
            "pmid": "12361443",
            "pub_year": 2002,
            "title": "Illness among schoolchildren during influenza season: Effect on school absenteeism, parental absenteeism from work, and secondary illness in families",
            "volume": "156"
        },
        "bib0260": {
            "authors": [
                {
                    "first": "J. P.",
                    "initial": "J.P.",
                    "last": "Amorij"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Huckriede"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wilschut"
                },
                {
                    "first": "H. W.",
                    "initial": "H.W.",
                    "last": "Frijlink"
                },
                {
                    "first": "W. L.J.",
                    "initial": "W.L.J.",
                    "last": "Hinrichs"
                }
            ],
            "doi": "10.1007/s11095-008-9559-6",
            "firstpage": "1256",
            "issn": "07248741",
            "lastpage": "1273",
            "pmid": "18338241",
            "pub_year": 2008,
            "title": "Development of stable influenza vaccine powder formulations: Challenges and possibilities",
            "volume": "25"
        },
        "bib0265": {
            "authors": [
                {
                    "first": "Eric J.",
                    "initial": "E.J.",
                    "last": "Kasowski"
                },
                {
                    "first": "Rebecca J.",
                    "initial": "R.J.",
                    "last": "Garten"
                },
                {
                    "first": "Carolyn B.",
                    "initial": "C.B.",
                    "last": "Bridges"
                }
            ],
            "doi": "10.1093/cid/ciq010",
            "firstpage": "S44",
            "issn": "10584838",
            "lastpage": "S49",
            "pmid": "21342899",
            "pub_year": 2011,
            "title": "Influenza pandemic epidemiologic and virologic diversity: Reminding ourselves of the possibilities",
            "volume": "52"
        },
        "bib0270": {
            "authors": [
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Gerhard"
                }
            ],
            "firstpage": "171",
            "issn": "0070217X",
            "lastpage": "190",
            "pmid": "11443873",
            "pub_year": 2001,
            "title": "The role of the antibody response in influenza virus infection",
            "volume": "260"
        },
        "bib0275": {
            "authors": [
                {
                    "first": "Robert G.",
                    "initial": "R.G.",
                    "last": "Webster"
                },
                {
                    "first": "Elena A.",
                    "initial": "E.A.",
                    "last": "Govorkova"
                }
            ],
            "doi": "10.1111/nyas.12462",
            "firstpage": "115",
            "issn": "00778923",
            "lastpage": "139",
            "pmid": "24891213",
            "pub_year": 2014,
            "title": "Continuing challenges in influenza",
            "volume": "1323"
        },
        "bib0280": {
            "authors": [
                {
                    "first": "Thomas G.",
                    "initial": "T.G.",
                    "last": "Boyce"
                },
                {
                    "first": "Henry H.",
                    "initial": "H.H.",
                    "last": "Hsu"
                },
                {
                    "first": "Edith C.",
                    "initial": "E.C.",
                    "last": "Sannella"
                },
                {
                    "first": "Shanita D.",
                    "initial": "S.D.",
                    "last": "Coleman-Dockery"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Baylis"
                },
                {
                    "first": "Yuwei",
                    "initial": "Y.",
                    "last": "Zhu"
                },
                {
                    "first": "Gail",
                    "initial": "G.",
                    "last": "Barchfeld"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "Difrancesco"
                },
                {
                    "first": "Mallikharjun",
                    "initial": "M.",
                    "last": "Paranandi"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Culley"
                },
                {
                    "first": "Kathleen M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "Peter F.",
                    "initial": "P.F.",
                    "last": "Wright"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00171-7",
            "firstpage": "217",
            "issn": "0264410X",
            "lastpage": "226",
            "pmid": "10930676",
            "pub_year": 2000,
            "title": "Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults",
            "volume": "19"
        },
        "bib0285": {
            "authors": [
                {
                    "first": "T. G.",
                    "initial": "T.G.",
                    "last": "Boyce"
                },
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Poland"
                }
            ],
            "doi": "10.1016/S0753-3322(00)89027-7",
            "firstpage": "210",
            "issn": "07533322",
            "lastpage": "218",
            "pmid": "10872719",
            "pub_year": 2000,
            "title": "Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: A review",
            "volume": "54"
        },
        "bib0290": {
            "authors": [
                {
                    "first": "Vittorio",
                    "initial": "V.",
                    "last": "Demicheli"
                }
            ],
            "firstpage": "282",
            "issn": "15927830",
            "lastpage": "285",
            "pmid": "21061710",
            "pub_year": 2010,
            "title": "Epidemiology and prevention of influenza",
            "volume": "32"
        },
        "bib0295": {
            "authors": [
                {
                    "first": "Anthony E.",
                    "initial": "A.E.",
                    "last": "Fiore"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Shay"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Broder"
                },
                {
                    "first": "John K.",
                    "initial": "J.K.",
                    "last": "Iskander"
                },
                {
                    "first": "Timothy M.",
                    "initial": "T.M.",
                    "last": "Uyeki"
                },
                {
                    "first": "Gina",
                    "initial": "G.",
                    "last": "Mootrey"
                },
                {
                    "first": "Joseph S.",
                    "initial": "J.S.",
                    "last": "Bresee"
                },
                {
                    "first": "Nancy J.",
                    "initial": "N.J.",
                    "last": "Cox"
                }
            ],
            "firstpage": "1",
            "issn": "01492195",
            "lastpage": "52",
            "pmid": "19644442",
            "pub_year": 2009,
            "title": "Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009",
            "volume": "58"
        },
        "bib0300": {
            "authors": [
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Wilschut"
                }
            ],
            "doi": "10.1016/j.imlet.2008.11.007",
            "firstpage": "118",
            "issn": "01652478",
            "lastpage": "121",
            "pmid": "19100779",
            "pub_year": 2009,
            "title": "Influenza vaccines: The virosome concept",
            "volume": "122"
        },
        "bib0305": {
            "authors": [
                {
                    "first": "Robert L.",
                    "initial": "R.L.",
                    "last": "Atmar"
                },
                {
                    "first": "Wendy A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "Shital M.",
                    "initial": "S.M.",
                    "last": "Patel"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                },
                {
                    "first": "Dewei",
                    "initial": "D.",
                    "last": "She"
                },
                {
                    "first": "Hana",
                    "initial": "H.",
                    "last": "El Sahly"
                },
                {
                    "first": "Justine",
                    "initial": "J.",
                    "last": "Pompey"
                },
                {
                    "first": "Thomas R.",
                    "initial": "T.R.",
                    "last": "Cate"
                },
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Couch"
                }
            ],
            "doi": "10.1086/508174",
            "firstpage": "1135",
            "issn": "10584838",
            "lastpage": "1142",
            "pmid": "17029131",
            "pub_year": 2006,
            "title": "Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations",
            "volume": "43"
        },
        "bib0310": {
            "authors": [
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Groth"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Borkowski"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Pellegrini"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.02.004",
            "firstpage": "6291",
            "issn": "0264410X",
            "lastpage": "6295",
            "pmid": "19840662",
            "pub_year": 2009,
            "title": "MF59\u00ae-adjuvanted influenza vaccine (FLUAD\u00ae) in children: Safety and immunogenicity following a second year seasonal vaccination",
            "volume": "27"
        },
        "bib0315": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Pellegrini"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Groth"
                },
                {
                    "first": "Astrid",
                    "initial": "A.",
                    "last": "Borkowski"
                },
                {
                    "first": "Derek T.",
                    "initial": "D.T.",
                    "last": "Hagan"
                },
                {
                    "first": "Audino",
                    "initial": "A.",
                    "last": "Podda"
                }
            ],
            "doi": "10.1097/INF.0b013e31819d6394",
            "firstpage": "563",
            "issn": "08913668",
            "lastpage": "571",
            "pub_year": 2009,
            "title": "Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant",
            "volume": "28"
        },
        "bib0320": {
            "authors": [
                {
                    "first": "Kathleen Maletic",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "Janet A.",
                    "initial": "J.A.",
                    "last": "Englund"
                }
            ],
            "doi": "10.1016/j.jpeds.2006.09.002",
            "firstpage": "737",
            "issn": "00223476",
            "lastpage": "738",
            "pmid": "17137882",
            "pub_year": 2006,
            "title": "Influenza vaccine for young children: Two doses are better than one",
            "volume": "149"
        },
        "bib0325": {
            "authors": [
                {
                    "first": "H. F.",
                    "initial": "H.F.",
                    "last": "Maassab"
                },
                {
                    "first": "Carole A.",
                    "initial": "C.A.",
                    "last": "Heilman"
                },
                {
                    "first": "M. Louise",
                    "initial": "M.L.",
                    "last": "Herlocher"
                }
            ],
            "firstpage": "203",
            "issn": "07362293",
            "lastpage": "242",
            "pmid": "2222834",
            "pub_year": 1990,
            "title": "Cold-adapted influenza viruses for use as live vaccines for man",
            "volume": "14"
        },
        "bib0330": {
            "authors": [
                {
                    "first": "H. F.",
                    "initial": "H.F.",
                    "last": "Maassab"
                }
            ],
            "firstpage": "728",
            "issn": "00221767",
            "lastpage": "732",
            "pmid": "5773321",
            "pub_year": 1969,
            "title": "Biologic and immunologic characteristics of cold-adapted influenza virus.",
            "volume": "102"
        },
        "bib0335": {
            "authors": [
                {
                    "first": "M. D.",
                    "initial": "M.D.",
                    "last": "Wareing"
                },
                {
                    "first": "G. A.",
                    "initial": "G.A.",
                    "last": "Tannock"
                }
            ],
            "doi": "10.1016/S0264-410X(01)00045-7",
            "firstpage": "3320",
            "issn": "0264410X",
            "lastpage": "3330",
            "pmid": "11348696",
            "pub_year": 2001,
            "title": "Live attenuated vaccines against influenza; an historical review",
            "volume": "19"
        },
        "bib0340": {
            "authors": [
                {
                    "first": "Brian R.",
                    "initial": "B.R.",
                    "last": "Murphy"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Coelingh"
                }
            ],
            "doi": "10.1089/08828240260066242",
            "firstpage": "295",
            "issn": "08828245",
            "lastpage": "323",
            "pmid": "12081014",
            "pub_year": 2002,
            "title": "Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines",
            "volume": "15"
        },
        "bib0345": {
            "authors": [
                {
                    "first": "Robert B.",
                    "initial": "R.B.",
                    "last": "Belshe"
                },
                {
                    "first": "Paul M.",
                    "initial": "P.M.",
                    "last": "Mendelman"
                }
            ],
            "doi": "10.1016/S0889-8561(03)00098-5",
            "firstpage": "745",
            "issn": "08898561",
            "lastpage": "767",
            "pmid": "14753390",
            "pub_year": 2003,
            "title": "Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent",
            "volume": "23"
        },
        "bib0350": {
            "authors": [
                {
                    "first": "H. F.",
                    "initial": "H.F.",
                    "last": "Maassab"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Francis"
                },
                {
                    "first": "F. M.",
                    "initial": "F.M.",
                    "last": "Davenport"
                },
                {
                    "first": "A. V.",
                    "initial": "A.V.",
                    "last": "Hennessy"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Minuse"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Anderson"
                }
            ],
            "firstpage": "589",
            "issn": "00429686",
            "lastpage": "594",
            "pmid": "5309481",
            "pub_year": 1969,
            "title": "Laboratory and clinical characteristics of attenuated strains of influenza virus.",
            "volume": "41"
        },
        "bib0355": {
            "authors": [
                {
                    "first": "Hunein F.",
                    "initial": "H.F.",
                    "last": "Maassab"
                },
                {
                    "first": "Martin L.",
                    "initial": "M.L.",
                    "last": "Bryant"
                }
            ],
            "doi": "10.1002/(SICI)1099-1654(199910/12)9:4<237::AID-RMV252>3.0.CO;2-G",
            "firstpage": "237",
            "issn": "10529276",
            "lastpage": "244",
            "pmid": "10578119",
            "pub_year": 1999,
            "title": "The development of live attenuated cold-adapted influenza virus vaccine for humans",
            "volume": "9"
        },
        "bib0360": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "Micki",
                    "initial": "M.",
                    "last": "Hultquist"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Walker"
                }
            ],
            "doi": "10.1128/AAC.00517-07",
            "firstpage": "4001",
            "issn": "00664804",
            "lastpage": "4008",
            "pmid": "17724151",
            "pub_year": 2007,
            "title": "Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects",
            "volume": "51"
        },
        "bib0365": null,
        "bib0370": {
            "authors": [
                {
                    "first": "Larisa",
                    "initial": "L.",
                    "last": "Rudenko"
                },
                {
                    "first": "Han",
                    "initial": "H.",
                    "last": "van den Bosch"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Kiseleva"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Mironov"
                },
                {
                    "first": "Anatoly",
                    "initial": "A.",
                    "last": "Naikhin"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "Larionova"
                },
                {
                    "first": "Dimitry",
                    "initial": "D.",
                    "last": "Bushmenkov"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.122",
            "firstpage": "A40",
            "issn": "0264410X",
            "lastpage": "A44",
            "pmid": "21684428",
            "pub_year": 2011,
            "title": "Live attenuated pandemic influenza vaccine: Clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries",
            "volume": "29"
        },
        "bib0375": {
            "authors": [
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Belshe"
                },
                {
                    "first": "Min Shi",
                    "initial": "M.S.",
                    "last": "Lee"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Walker"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Stoddard"
                },
                {
                    "first": "Paul M.",
                    "initial": "P.M.",
                    "last": "Mendelman"
                }
            ],
            "doi": "10.1586/14760584.3.6.643",
            "firstpage": "643",
            "issn": "14760584",
            "lastpage": "654",
            "pmid": "15606348",
            "pub_year": 2004,
            "title": "Safety, immunogenicity and efficacy of intranasals, live attenuated influenza vaccine",
            "volume": "3"
        },
        "bib0380": {
            "authors": [
                {
                    "first": "Suzanne E.",
                    "initial": "S.E.",
                    "last": "Ohmit"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Victor"
                },
                {
                    "first": "Judy R.",
                    "initial": "J.R.",
                    "last": "Rotthoff"
                },
                {
                    "first": "Esther R.",
                    "initial": "E.R.",
                    "last": "Teich"
                },
                {
                    "first": "Rachel K.",
                    "initial": "R.K.",
                    "last": "Truscon"
                },
                {
                    "first": "Laura L.",
                    "initial": "L.L.",
                    "last": "Baum"
                },
                {
                    "first": "Bhavya",
                    "initial": "B.",
                    "last": "Rangarajan"
                },
                {
                    "first": "Duane W.",
                    "initial": "D.W.",
                    "last": "Newton"
                },
                {
                    "first": "Matthew L.",
                    "initial": "M.L.",
                    "last": "Boulton"
                },
                {
                    "first": "Arnold S.",
                    "initial": "A.S.",
                    "last": "Monto"
                }
            ],
            "doi": "10.1056/NEJMoa061850",
            "firstpage": "2513",
            "issn": "00284793",
            "lastpage": "2522",
            "pmid": "17167134",
            "pub_year": 2006,
            "title": "Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines",
            "volume": "355"
        },
        "bib0385": {
            "authors": [
                {
                    "first": "Xiuhua",
                    "initial": "X.",
                    "last": "Lu"
                },
                {
                    "first": "Lindsay E.",
                    "initial": "L.E.",
                    "last": "Edwards"
                },
                {
                    "first": "Julia A.",
                    "initial": "J.A.",
                    "last": "Desheva"
                },
                {
                    "first": "Doan C.",
                    "initial": "D.C.",
                    "last": "Nguyen"
                },
                {
                    "first": "Andrey",
                    "initial": "A.",
                    "last": "Rekstin"
                },
                {
                    "first": "Iain",
                    "initial": "I.",
                    "last": "Stephenson"
                },
                {
                    "first": "Kristy",
                    "initial": "K.",
                    "last": "Szretter"
                },
                {
                    "first": "Nancy J.",
                    "initial": "N.J.",
                    "last": "Cox"
                },
                {
                    "first": "Larisa G.",
                    "initial": "L.G.",
                    "last": "Rudenko"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Klimov"
                },
                {
                    "first": "Jacqueline M.",
                    "initial": "J.M.",
                    "last": "Katz"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.05.039",
            "firstpage": "6588",
            "issn": "0264410X",
            "lastpage": "6593",
            "pmid": "17030078",
            "pub_year": 2006,
            "title": "Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses",
            "volume": "24"
        },
        "bib0390": null,
        "bib0395": {
            "authors": [
                {
                    "first": "Natalie J.",
                    "initial": "N.J.",
                    "last": "Carter"
                },
                {
                    "first": "Monique P.",
                    "initial": "M.P.",
                    "last": "Curran"
                }
            ],
            "doi": "10.2165/11206860-000000000-00000",
            "firstpage": "1591",
            "issn": "00126667",
            "lastpage": "1622",
            "pmid": "21861544",
            "pub_year": 2011,
            "title": "Live attenuated influenza vaccine (FluMist\u00ae; Fluenz\u2122): A review of its use in the prevention of seasonal influenza in children and adults",
            "volume": "71"
        },
        "bib0400": {
            "authors": [
                {
                    "first": "Sherif B.",
                    "initial": "S.B.",
                    "last": "Mossad"
                }
            ],
            "doi": "10.3949/ccjm.70.9.801",
            "firstpage": "801",
            "issn": "08911150",
            "lastpage": "806",
            "pmid": "14518575",
            "pub_year": 2003,
            "title": "Demystifying FluMist, a new intranasal, live influenza vaccine",
            "volume": "70"
        },
        "bib0405": null,
        "bib0410": {
            "authors": [
                {
                    "first": "Prasad S.",
                    "initial": "P.S.",
                    "last": "Kulkarni"
                },
                {
                    "first": "Sidram K.",
                    "initial": "S.K.",
                    "last": "Raut"
                },
                {
                    "first": "Rajeev M.",
                    "initial": "R.M.",
                    "last": "Dhere"
                }
            ],
            "doi": "10.4161/hv.22317",
            "firstpage": "122",
            "issn": "21645515",
            "lastpage": "124",
            "pmid": "23442586",
            "pub_year": 2013,
            "title": "A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac\u00ae) in India",
            "volume": "9"
        },
        "bib0415": null,
        "bib0420": {
            "authors": [
                {
                    "first": "Chengjun",
                    "initial": "C.",
                    "last": "Mo"
                },
                {
                    "first": "Ryan",
                    "initial": "R.",
                    "last": "Yamagata"
                },
                {
                    "first": "Alfred",
                    "initial": "A.",
                    "last": "Pan"
                },
                {
                    "first": "Jhansi",
                    "initial": "J.",
                    "last": "Reddy"
                },
                {
                    "first": "Nisha",
                    "initial": "N.",
                    "last": "Hazari"
                },
                {
                    "first": "Gregory",
                    "initial": "G.",
                    "last": "Duke"
                }
            ],
            "doi": "10.1016/j.jviromet.2008.03.006",
            "firstpage": "63",
            "issn": "01660934",
            "lastpage": "69",
            "pmid": "18423899",
            "pub_year": 2008,
            "title": "Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca/ts phenotype",
            "volume": "150"
        },
        "bib0425": {
            "authors": [
                {
                    "first": "Mark C.",
                    "initial": "M.C.",
                    "last": "Steinhoff"
                },
                {
                    "first": "Neal A.",
                    "initial": "N.A.",
                    "last": "Hasley"
                },
                {
                    "first": "Modena H.",
                    "initial": "M.H.",
                    "last": "Wilson"
                },
                {
                    "first": "Barbara A.",
                    "initial": "B.A.",
                    "last": "Burns"
                },
                {
                    "first": "Roberta K.",
                    "initial": "R.K.",
                    "last": "Samorodin"
                },
                {
                    "first": "Louis F.",
                    "initial": "L.F.",
                    "last": "Fries"
                },
                {
                    "first": "Brian R.",
                    "initial": "B.R.",
                    "last": "Murphy"
                },
                {
                    "first": "Mary Lou",
                    "initial": "M.L.",
                    "last": "Clements"
                }
            ],
            "doi": "10.1093/infdis/162.2.394",
            "firstpage": "394",
            "issn": "00221899",
            "lastpage": "401",
            "pmid": "2197335",
            "pub_year": 1990,
            "title": "Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children",
            "volume": "162"
        },
        "bib0430": {
            "authors": [
                {
                    "first": "L. J.",
                    "initial": "L.J.",
                    "last": "Reed"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Muench"
                }
            ],
            "doi": "10.1093/oxfordjournals.aje.a118408",
            "firstpage": "493",
            "issn": "00029262",
            "lastpage": "497",
            "pub_year": 1938,
            "title": "A simple method of estimating fifty per cent endpoints",
            "volume": "27"
        },
        "bib0435": {
            "authors": [
                {
                    "first": "Tim J.",
                    "initial": "T.J.",
                    "last": "Kamerzell"
                },
                {
                    "first": "Reza",
                    "initial": "R.",
                    "last": "Esfandiary"
                },
                {
                    "first": "Sangeeta B.",
                    "initial": "S.B.",
                    "last": "Joshi"
                },
                {
                    "first": "C. Russell",
                    "initial": "C.R.",
                    "last": "Middaugh"
                },
                {
                    "first": "David B.",
                    "initial": "D.B.",
                    "last": "Volkin"
                }
            ],
            "doi": "10.1016/j.addr.2011.07.006",
            "firstpage": "1118",
            "issn": "0169409X",
            "lastpage": "1159",
            "pmid": "21855584",
            "pub_year": 2011,
            "title": "Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development",
            "volume": "63"
        },
        "bib0440": null,
        "bib0445": {
            "authors": [
                {
                    "first": "Brent S.",
                    "initial": "B.S.",
                    "last": "Kendrick"
                },
                {
                    "first": "Jeffrey D.",
                    "initial": "J.D.",
                    "last": "Meyer"
                },
                {
                    "first": "James E.",
                    "initial": "J.E.",
                    "last": "Matsuura"
                },
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Carpenter"
                },
                {
                    "first": "Mark C.",
                    "initial": "M.C.",
                    "last": "Manning"
                }
            ],
            "doi": "10.1006/abbi.1997.0327",
            "firstpage": "113",
            "issn": "00039861",
            "lastpage": "118",
            "pmid": "9344471",
            "pub_year": 1997,
            "title": "Hydrophobic ion pairing as a method for enhancing structure and activity of lyophilized subtilisin BPN' suspended in isooctane",
            "volume": "347"
        },
        "bib0450": {
            "authors": [
                {
                    "first": "Satoshi",
                    "initial": "S.",
                    "last": "Ohtake"
                },
                {
                    "first": "Russell A.",
                    "initial": "R.A.",
                    "last": "Martin"
                },
                {
                    "first": "Luisa",
                    "initial": "L.",
                    "last": "Yee"
                },
                {
                    "first": "Dexiang",
                    "initial": "D.",
                    "last": "Chen"
                },
                {
                    "first": "Debra D.",
                    "initial": "D.D.",
                    "last": "Kristensen"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Lechuga-Ballesteros"
                },
                {
                    "first": "Vu",
                    "initial": "V.",
                    "last": "Truong-Le"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.11.024",
            "firstpage": "1275",
            "issn": "0264410X",
            "lastpage": "1284",
            "pmid": "19944152",
            "pub_year": 2010,
            "title": "Heat-stable measles vaccine produced by spray drying",
            "volume": "28"
        },
        "bib0455": {
            "authors": [
                {
                    "first": "Steven P.",
                    "initial": "S.P.",
                    "last": "Schwendeman"
                },
                {
                    "first": "Henry R.",
                    "initial": "H.R.",
                    "last": "Costantino"
                },
                {
                    "first": "Rajesh K.",
                    "initial": "R.K.",
                    "last": "Gupta"
                },
                {
                    "first": "George R.",
                    "initial": "G.R.",
                    "last": "Siber"
                },
                {
                    "first": "Alexander M.",
                    "initial": "A.M.",
                    "last": "Klibanov"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Langer"
                }
            ],
            "doi": "10.1073/pnas.92.24.11234",
            "firstpage": "11234",
            "issn": "00278424",
            "lastpage": "11238",
            "pmid": "7479971",
            "pub_year": 1995,
            "title": "Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation",
            "volume": "92"
        },
        "bib0460": {
            "authors": [
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Mumenthaler"
                },
                {
                    "first": "Chung C.",
                    "initial": "C.C.",
                    "last": "Hsu"
                },
                {
                    "first": "Rodney",
                    "initial": "R.",
                    "last": "Pearlman"
                }
            ],
            "doi": "10.1023/A:1018929224005",
            "firstpage": "12",
            "issn": "07248741",
            "lastpage": "20",
            "pmid": "8140042",
            "pub_year": 1994,
            "title": "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator",
            "volume": "11"
        },
        "bib0465": {
            "authors": [
                {
                    "first": "Tsutomu",
                    "initial": "T.",
                    "last": "Arakawa"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Ejima"
                },
                {
                    "first": "Kouhei",
                    "initial": "K.",
                    "last": "Tsumoto"
                },
                {
                    "first": "Noriyuki",
                    "initial": "N.",
                    "last": "Obeyama"
                },
                {
                    "first": "Yoshikazu",
                    "initial": "Y.",
                    "last": "Tanaka"
                },
                {
                    "first": "Yoshiko",
                    "initial": "Y.",
                    "last": "Kita"
                },
                {
                    "first": "Serge N.",
                    "initial": "S.N.",
                    "last": "Timasheff"
                }
            ],
            "doi": "10.1016/j.bpc.2006.12.007",
            "firstpage": "1",
            "issn": "03014622",
            "lastpage": "8",
            "pmid": "17257734",
            "pub_year": 2007,
            "title": "Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects",
            "volume": "127"
        },
        "bib0470": {
            "authors": [
                {
                    "first": "Ken Ichi",
                    "initial": "K.I.",
                    "last": "Izutsu"
                },
                {
                    "first": "Yasuto",
                    "initial": "Y.",
                    "last": "Fujimaki"
                },
                {
                    "first": "Akiko",
                    "initial": "A.",
                    "last": "Kuwabara"
                },
                {
                    "first": "Nobuo",
                    "initial": "N.",
                    "last": "Aoyagi"
                }
            ],
            "doi": "10.1016/j.ijpharm.2005.05.019",
            "firstpage": "161",
            "issn": "03785173",
            "lastpage": "169",
            "pmid": "16026945",
            "pub_year": 2005,
            "title": "Effect of counterions on the physical properties of L-arginine in frozen solutions and freeze-dried solids",
            "volume": "301"
        },
        "bib0475": {
            "authors": [
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Pikal"
                },
                {
                    "first": "Karen M.",
                    "initial": "K.M.",
                    "last": "Dellerman"
                },
                {
                    "first": "Michael L.",
                    "initial": "M.L.",
                    "last": "Roy"
                },
                {
                    "first": "Ralph M.",
                    "initial": "R.M.",
                    "last": "Riggin"
                }
            ],
            "doi": "10.1023/A:1015834724528",
            "firstpage": "427",
            "issn": "07248741",
            "lastpage": "436",
            "pmid": "1871037",
            "pub_year": 1991,
            "title": "The Effects of Formulation Variables on the Stability of Freeze-Dried Human Growth Hormone",
            "volume": "8"
        },
        "bib0480": {
            "authors": [
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Mistilis"
                },
                {
                    "first": "Andreas S.",
                    "initial": "A.S.",
                    "last": "Bommarius"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Prausnitz"
                }
            ],
            "doi": "10.1002/jps.24283",
            "firstpage": "740",
            "issn": "00223549",
            "lastpage": "749",
            "pmid": "25448542",
            "pub_year": 2015,
            "title": "Development of a thermostable microneedle patch for influenza vaccination",
            "volume": "104"
        },
        "bib0485": {
            "authors": [
                {
                    "first": "Daming",
                    "initial": "D.",
                    "last": "Zhu"
                },
                {
                    "first": "Holly",
                    "initial": "H.",
                    "last": "McClellan"
                },
                {
                    "first": "Weili",
                    "initial": "W.",
                    "last": "Dai"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Gebregeorgis"
                },
                {
                    "first": "Mary Anne",
                    "initial": "M.A.",
                    "last": "Kidwell"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Aebig"
                },
                {
                    "first": "Kelly M.",
                    "initial": "K.M.",
                    "last": "Rausch"
                },
                {
                    "first": "Laura B.",
                    "initial": "L.B.",
                    "last": "Martin"
                },
                {
                    "first": "Ruth D.",
                    "initial": "R.D.",
                    "last": "Ellis"
                },
                {
                    "first": "Louis",
                    "initial": "L.",
                    "last": "Miller"
                },
                {
                    "first": "Yimin",
                    "initial": "Y.",
                    "last": "Wu"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.015",
            "firstpage": "3640",
            "issn": "0264410X",
            "lastpage": "3645",
            "pmid": "21440641",
            "pub_year": 2011,
            "title": "Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide\u00ae ISA 720 and stabilized with glycine",
            "volume": "29"
        },
        "bib0490": {
            "authors": [
                {
                    "first": "Haripada",
                    "initial": "H.",
                    "last": "Maity"
                },
                {
                    "first": "Cyrus",
                    "initial": "C.",
                    "last": "Karkaria"
                },
                {
                    "first": "Juan",
                    "initial": "J.",
                    "last": "Davagnino"
                }
            ],
            "doi": "10.2174/138920109789069297",
            "firstpage": "609",
            "issn": "13892010",
            "lastpage": "625",
            "pmid": "19619121",
            "pub_year": 2009,
            "title": "Effects of pH and arginine on the solubility and stability of a therapeutic protein (fibroblast growth factor 20): Relationship between solubility and stability",
            "volume": "10"
        },
        "bib0495": {
            "authors": [
                {
                    "first": "Haripada",
                    "initial": "H.",
                    "last": "Maity"
                },
                {
                    "first": "Courtney",
                    "initial": "C.",
                    "last": "O'Dell"
                },
                {
                    "first": "Arvind",
                    "initial": "A.",
                    "last": "Srivastava"
                },
                {
                    "first": "Joel",
                    "initial": "J.",
                    "last": "Goldstein"
                }
            ],
            "doi": "10.2174/138920109789978711",
            "firstpage": "761",
            "issn": "13892010",
            "lastpage": "766",
            "pmid": "19939215",
            "pub_year": 2009,
            "title": "Effects of arginine on photostability and thermal stability of IgG1 monoclonal antibodies",
            "volume": "10"
        },
        "bib0500": {
            "authors": [
                {
                    "first": "A. David",
                    "initial": "A.D.",
                    "last": "Woolfson"
                },
                {
                    "first": "Manish L.",
                    "initial": "M.L.",
                    "last": "Umrethia"
                },
                {
                    "first": "Victoria L.",
                    "initial": "V.L.",
                    "last": "Kett"
                },
                {
                    "first": "R. Karl",
                    "initial": "R.K.",
                    "last": "Malcolm"
                }
            ],
            "doi": "10.1016/j.ijpharm.2009.12.042",
            "firstpage": "136",
            "issn": "03785173",
            "lastpage": "143",
            "pmid": "20045043",
            "pub_year": 2010,
            "title": "Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: Optimisation by an artificial neural network",
            "volume": "388"
        }
    },
    "body_text": [
        {
            "endOffset": 36426,
            "parents": [],
            "secId": "sec0030",
            "sentence": "In addition, we tested wider concentration ranges for excipients to find the upper and lower limits of stability improvement.",
            "startOffset": 36301,
            "title": "Results"
        },
        {
            "endOffset": 35044,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "The decay rate was determined using the slope of the stability data in a linear regression model (GraphPad Prism software version 6).",
            "startOffset": 34911,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 30411,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0420": {
                    "endOffset": 30410,
                    "startOffset": 30403
                },
                "bib0425": {
                    "endOffset": 30410,
                    "startOffset": 30403
                },
                "bib0430": {
                    "endOffset": 30410,
                    "startOffset": 30403
                }
            },
            "secId": "sec0015",
            "sentence": "A tissue culture infectious dose50 (TCID50) procedure based on published methods was adapted for use with a colorimetric dye to determine the viral titer of influenza vaccine formulations [34\u201336].",
            "startOffset": 30215,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 40193,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Based on three stability experiments, for H1N1 formulated at a titer of 2 \u00d7 106 log10 TCID50/mL with SPG and 1% arginine, the lower 95% confidence interval for the time to reach 1 log loss was 32.2 weeks and 2.5 weeks at 2\u20138 \u00b0C and 25 \u00b0C, respectively.",
            "startOffset": 39941,
            "title": "Results"
        },
        {
            "endOffset": 37362,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The formulation containing 1% arginine and 0.5% BSA showed the largest stability improvement at 25 \u00b0C and 33 \u00b0C (Fig. 2B and C).",
            "startOffset": 37234,
            "title": "Results"
        },
        {
            "endOffset": 33957,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Formulations were prepared by diluting bulk vaccine into the formulations at a 1:10 ratio to achieve a final live virus titer of 2 \u00d7 106 log10 TCID50/mL or where noted at a 1:5 ratio to achieve a final live virus titer of 1 \u00d7 107 log10 TCID50/mL.",
            "startOffset": 33711,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 28171,
            "parents": [],
            "refoffsets": {
                "bib0375": {
                    "endOffset": 28170,
                    "startOffset": 28166
                }
            },
            "secId": "sec0005",
            "sentence": "Although no clear correlates of immunity for LAIV are defined, immune protection has been associated with serum hemagglutination-inhibition antibody and secretory immunoglobulin A (IgA) [25].",
            "startOffset": 27980,
            "title": "Introduction"
        },
        {
            "endOffset": 26776,
            "parents": [],
            "refoffsets": {
                "bib0260": {
                    "endOffset": 26775,
                    "startOffset": 26767
                },
                "bib0280": {
                    "endOffset": 26775,
                    "startOffset": 26767
                },
                "bib0285": {
                    "endOffset": 26775,
                    "startOffset": 26767
                },
                "bib0290": {
                    "endOffset": 26775,
                    "startOffset": 26767
                },
                "bib0295": {
                    "endOffset": 26775,
                    "startOffset": 26767
                },
                "bib0300": {
                    "endOffset": 26775,
                    "startOffset": 26767
                }
            },
            "secId": "sec0005",
            "sentence": "IIVs are licensed for intramuscular delivery to anyone six months of age or older and exist as inactivated whole virus particles or as split virion and recombinant subunit vaccines [2,6\u201310].",
            "startOffset": 26586,
            "title": "Introduction"
        },
        {
            "endOffset": 28551,
            "parents": [],
            "secId": "sec0005",
            "sentence": "LAIVs could be more widely used if they were stable at 2\u20138 \u00b0C for 1 year, or an entire influenza season.",
            "startOffset": 28447,
            "title": "Introduction"
        },
        {
            "endOffset": 27868,
            "parents": [],
            "refoffsets": {
                "bib0295": {
                    "endOffset": 27867,
                    "startOffset": 27855
                },
                "bib0345": {
                    "endOffset": 27867,
                    "startOffset": 27855
                },
                "bib0360": {
                    "endOffset": 27867,
                    "startOffset": 27855
                },
                "bib0365": {
                    "endOffset": 27867,
                    "startOffset": 27855
                }
            },
            "secId": "sec0005",
            "sentence": "Flumist\u00ae (MedImmune Vaccines Inc., Gaithersburg, Maryland, United States), a licensed LAIV, is delivered intranasally and is approved for use in healthy, non-pregnant subjects 2\u201349 years old [9,19,22,23].",
            "startOffset": 27664,
            "title": "Introduction"
        },
        {
            "endOffset": 40308,
            "parents": [],
            "secId": "sec0030",
            "sentence": "One experiment was performed with type B formulated at a titer of 2 \u00d7 106 log10 TCID50/mL with SPG and 1% arginine.",
            "startOffset": 40193,
            "title": "Results"
        },
        {
            "endOffset": 34382,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "We selected a temperature of 33 \u00b0C for stability testing to improve resolution of the decay rate.",
            "startOffset": 34285,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 39226,
            "parents": [],
            "secId": "sec0030",
            "sentence": "However, at 33 \u00b0C, H1N1 formulations with 1% arginine or 1% arginine with 0.5% rHSA showed similar stability.",
            "startOffset": 39117,
            "title": "Results"
        },
        {
            "endOffset": 40769,
            "parents": [],
            "secId": "sec0030",
            "sentence": "For Type B, the time to 1 log10 loss at the higher concentration was 37.5 weeks and 3.4 weeks.",
            "startOffset": 40675,
            "title": "Results"
        },
        {
            "endOffset": 45316,
            "parents": [],
            "secId": "sec0035",
            "sentence": "FluMist\u00ae was developed for vaccine strains based on use of the A/Ann Arbor/6/60 or B/Ann Arbor/6/66 genetic background.",
            "startOffset": 45197,
            "title": "Discussion"
        },
        {
            "endOffset": 35440,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Final decay rates are from the lower 95% confidence interval based on three formulation experiments.",
            "startOffset": 35340,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 25503,
            "parents": [],
            "refoffsets": {
                "bib0260": {
                    "endOffset": 25439,
                    "startOffset": 25436
                },
                "bib0265": {
                    "endOffset": 25502,
                    "startOffset": 25499
                }
            },
            "secId": "sec0005",
            "sentence": "Vaccination is essential to prevent influenza virus infections [2] and is especially important to prevent influenza pandemics [3].",
            "startOffset": 25373,
            "title": "Introduction"
        },
        {
            "endOffset": 40674,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Stability testing with a higher dose of LAIV was performed only once, but the time to 1 log10 loss for H1N1 at a titer of 1 \u00d7 107 log10 TCID50/mL formulated in SPG with 1% arginine was 36.1 weeks and 2.6 weeks at 2\u20138 \u00b0C and 25 \u00b0C, respectively.",
            "startOffset": 40430,
            "title": "Results"
        },
        {
            "endOffset": 31650,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Lyophilized LAIV (NASOVAC\u00ae) supplied by SIIL was stored at \u221230 \u00b0C (to prevent any measureable loss in titer during these studies) in single-use aliquots for an assay control.",
            "startOffset": 31476,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 26036,
            "parents": [],
            "refoffsets": {
                "bib0270": {
                    "endOffset": 26035,
                    "startOffset": 26032
                }
            },
            "secId": "sec0005",
            "sentence": "Point mutations in viral RNA during viral replication cause antigenic drift [4].",
            "startOffset": 25956,
            "title": "Introduction"
        },
        {
            "endOffset": 46074,
            "parents": [],
            "secId": "sec0040",
            "sentence": "The authors are employed by PATH, a nonprofit international health organization, and received grant funding to advance research to assess the technical and commercial viability of improving the stability of vaccines of importance to developing countries.",
            "startOffset": 45820,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 29507,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 29506,
                    "startOffset": 29499
                },
                "bib0415": {
                    "endOffset": 29506,
                    "startOffset": 29499
                }
            },
            "secId": "sec0005",
            "sentence": "Although SIIL developed a commercial LAIV H1N1 vaccine, to achieve a one-year shelf life at 2\u20138 \u00b0C, the lyophilized product is costly and requires multiple handling steps before administration, limiting its programmatic suitability [22,33].",
            "startOffset": 29267,
            "title": "Introduction"
        },
        {
            "endOffset": 31709,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bib0430": {
                    "endOffset": 31708,
                    "startOffset": 31704
                }
            },
            "secId": "sec0015",
            "sentence": "Titers were determined using the Reed-Muench formula [36].",
            "startOffset": 31651,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 41296,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Agitation and freeze\u2013thaw were performed to mimic what a vaccine vial might encounter during shipment or storage (Fig. 5).",
            "startOffset": 41174,
            "title": "Results"
        },
        {
            "endOffset": 34642,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Lead formulations were repeated in subsequent formulation experiments.",
            "startOffset": 34572,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 28446,
            "parents": [],
            "refoffsets": {
                "bib0365": {
                    "endOffset": 28445,
                    "startOffset": 28441
                }
            },
            "secId": "sec0005",
            "sentence": "FluMist\u00ae contains the same antigens as the IIV for that season and has reported stability of 18 weeks at 2\u20138 \u00b0C [23].",
            "startOffset": 28329,
            "title": "Introduction"
        },
        {
            "endOffset": 29266,
            "parents": [],
            "refoffsets": {
                "bib0370": {
                    "endOffset": 29265,
                    "startOffset": 29258
                },
                "bib0410": {
                    "endOffset": 29265,
                    "startOffset": 29258
                }
            },
            "secId": "sec0005",
            "sentence": "Serum Institute of India Ltd. (SIIL) was selected to produce monovalent LAIV and trivalent seasonal LAIV using the IEM vaccine donor virus backbone for influenza A and B viruses [24,32].",
            "startOffset": 29080,
            "title": "Introduction"
        },
        {
            "endOffset": 42782,
            "parents": [],
            "refoffsets": {
                "bib0450": {
                    "endOffset": 42781,
                    "startOffset": 42768
                },
                "bib0465": {
                    "endOffset": 42781,
                    "startOffset": 42768
                },
                "bib0480": {
                    "endOffset": 42781,
                    "startOffset": 42768
                },
                "bib0485": {
                    "endOffset": 42781,
                    "startOffset": 42768
                }
            },
            "secId": "sec0035",
            "sentence": "l-Arginine and l-glycine, for example, are common excipients for pharmaceutical applications [40,43,46,47].",
            "startOffset": 42675,
            "title": "Discussion"
        },
        {
            "endOffset": 38285,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Consistent with previous experiments, the use of 1% arginine led to statistically significant improvement in stability compared to use of SPG buffer alone at 2\u20138 \u00b0C (p-value <0.0001), 25 \u00b0C (p-value <0.0001), and 33 \u00b0C (p-value of 0.0002 and 0.003, respectively) for both H1N1 and type B (Fig. 3A\u2013C).",
            "startOffset": 37985,
            "title": "Results"
        },
        {
            "endOffset": 37602,
            "parents": [],
            "secId": "sec0030",
            "sentence": "HPMC and PVP appeared to destabilize LAIV and were not included in future formulations.",
            "startOffset": 37515,
            "title": "Results"
        },
        {
            "endOffset": 35295,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Statistically significant differences in the stability profiles of the lead excipients were evaluated by comparing slopes of linear regression lines using Prism software.",
            "startOffset": 35125,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 36300,
            "parents": [],
            "secId": "sec0030",
            "sentence": "In the second stage, lead formulations were optimized by combining excipients to further improve stability (Fig. 2).",
            "startOffset": 36184,
            "title": "Results"
        },
        {
            "endOffset": 25884,
            "parents": [],
            "refoffsets": {
                "bib0260": {
                    "endOffset": 25883,
                    "startOffset": 25878
                },
                "bib0270": {
                    "endOffset": 25883,
                    "startOffset": 25878
                }
            },
            "secId": "sec0005",
            "sentence": "Within each subtype, influenza viruses are further categorized based on antigenic determinants in their surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) [2,4].",
            "startOffset": 25710,
            "title": "Introduction"
        },
        {
            "endOffset": 31385,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "After viral replication, dye was added to detect cell viability.",
            "startOffset": 31321,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 44559,
            "parents": [],
            "secId": "sec0035",
            "sentence": "The turbidity could be due to the fatty acid content in HSA that is not present in rHSA.",
            "startOffset": 44471,
            "title": "Discussion"
        },
        {
            "endOffset": 25709,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Because only strains A and B cause respiratory disease, vaccines target these subtypes.",
            "startOffset": 25622,
            "title": "Introduction"
        },
        {
            "endOffset": 29777,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 29776,
                    "startOffset": 29772
                }
            },
            "secId": "sec0005",
            "sentence": "The development of a low-cost, liquid formulation that is stable for an entire influenza season would contribute to greater acceptance by manufacturers and wider use of LAIV while decreasing production and distribution costs by removing the need for lyophilization [22].",
            "startOffset": 29507,
            "title": "Introduction"
        },
        {
            "endOffset": 38425,
            "parents": [],
            "secId": "sec0030",
            "sentence": "To confirm the formulations selected, we tested a higher concentration (1 \u00d7 107 log10 TCID50/mL) of LAIV strains (H1N1 and type B) (Fig. 4).",
            "startOffset": 38285,
            "title": "Results"
        },
        {
            "endOffset": 34145,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Loss was determined by TCID50 assay.",
            "startOffset": 34109,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 45539,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Modern seasonal influenza vaccines contain three or four strains, so a formulation must sufficiently stabilize all included strains.",
            "startOffset": 45407,
            "title": "Discussion"
        },
        {
            "endOffset": 28328,
            "parents": [],
            "refoffsets": {
                "bib0375": {
                    "endOffset": 28327,
                    "startOffset": 28320
                },
                "bib0380": {
                    "endOffset": 28327,
                    "startOffset": 28320
                },
                "bib0385": {
                    "endOffset": 28327,
                    "startOffset": 28320
                },
                "bib0390": {
                    "endOffset": 28327,
                    "startOffset": 28320
                },
                "bib0395": {
                    "endOffset": 28327,
                    "startOffset": 28320
                },
                "bib0400": {
                    "endOffset": 28327,
                    "startOffset": 28320
                }
            },
            "secId": "sec0005",
            "sentence": "Also, randomized control trials found that LAIVs are more efficacious than IIVs in children, making them attractive for seasonal prevention efforts [25\u201330].",
            "startOffset": 28172,
            "title": "Introduction"
        },
        {
            "endOffset": 29079,
            "parents": [],
            "refoffsets": {
                "bib0370": {
                    "endOffset": 29078,
                    "startOffset": 29071
                },
                "bib0405": {
                    "endOffset": 29078,
                    "startOffset": 29071
                }
            },
            "secId": "sec0005",
            "sentence": "This support granted manufacturers access to strains necessary for producing vaccines, especially the live-attenuated master donor virus strain from the Institute of Experimental Medicine (IEM; St. Petersburg, Russia) [24,31].",
            "startOffset": 28853,
            "title": "Introduction"
        },
        {
            "endOffset": 36928,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations containing arginine alone (Formulation-09 at 1% and Formulation-12 at 3%), 1% arginine with BSA (Formulation-17 at 0.5% BSA and Formulation-18 at 9% BSA), and 1% arginine with 0.5% gelatin (Formulation-16) showed stability for the length of the experiment (20 weeks) at 2\u20138 \u00b0C (Fig. 2A).",
            "startOffset": 36628,
            "title": "Results"
        },
        {
            "endOffset": 26399,
            "parents": [],
            "refoffsets": {
                "bib0270": {
                    "endOffset": 26398,
                    "startOffset": 26395
                }
            },
            "secId": "sec0005",
            "sentence": "Immune responses generated by vaccination are directed against the HA and NA proteins [4].",
            "startOffset": 26309,
            "title": "Introduction"
        },
        {
            "endOffset": 40429,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The lower 95% confidence interval for the time to 1 log10 loss at 2\u20138 \u00b0C and 25 \u00b0C was 50.8 and 3.6 weeks, respectively.",
            "startOffset": 40309,
            "title": "Results"
        },
        {
            "endOffset": 41173,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations were prepared with LAIV strains at titers of 2 \u00d7 106 and 1 \u00d7 107 log10 TCID50/mL.",
            "startOffset": 41079,
            "title": "Results"
        },
        {
            "endOffset": 43659,
            "parents": [],
            "secId": "sec0035",
            "sentence": "In our experiments, only l-arginine with rHSA increased the stability of the LAIV strains tested.",
            "startOffset": 43562,
            "title": "Discussion"
        },
        {
            "endOffset": 44096,
            "parents": [],
            "secId": "sec0035",
            "sentence": "If a vaccine can withstand a freeze\u2013thaw cycle, freezing can be used to further increase shelf life by keeping the vaccine frozen at the manufacturing site and then initiating storage at 2\u20138 \u00b0C upon shipment or during short-term storage at the clinical site.",
            "startOffset": 43838,
            "title": "Discussion"
        },
        {
            "endOffset": 36000,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The addition of 1% arginine (Formulation 9) improved the stability of LAIV compared to SPG buffer alone (Formulation 1) at 25 \u00b0C.",
            "startOffset": 35871,
            "title": "Results"
        },
        {
            "endOffset": 32861,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Formulations were monitored for pH, osmolality, and appearance by visual inspection.",
            "startOffset": 32777,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 27396,
            "parents": [],
            "refoffsets": {
                "bib0295": {
                    "endOffset": 27395,
                    "startOffset": 27389
                },
                "bib0355": {
                    "endOffset": 27395,
                    "startOffset": 27389
                }
            },
            "secId": "sec0005",
            "sentence": "LAIVs express the antigenic phenotype of the target strain with the attenuated phenotype of the cold-adapted backbone, greatly reducing replication at body temperatures [9,21].",
            "startOffset": 27220,
            "title": "Introduction"
        },
        {
            "endOffset": 25621,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Influenza strains are characterized by surface glycoproteins and are classified into three types: A, B, and C strains.",
            "startOffset": 25503,
            "title": "Introduction"
        },
        {
            "endOffset": 30556,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "A Madin-Darby canine kidney (MDCK) cell line from Influenza Reagent Resource (IRR) was selected for use in this assay (IRR FR-58, Lot 58851661).",
            "startOffset": 30412,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 36495,
            "parents": [],
            "secId": "sec0030",
            "sentence": "We also evaluated additional excipients: lactalbumin, HPMC, and PVP.",
            "startOffset": 36427,
            "title": "Results"
        },
        {
            "endOffset": 31758,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "The assay variability was \u00b10.23 log10 TCID50/mL.",
            "startOffset": 31710,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 27522,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Replication of LAIV in the upper respiratory tract confers mucosal immunity and a circulating neutralizing antibody response.",
            "startOffset": 27397,
            "title": "Introduction"
        },
        {
            "endOffset": 37056,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations containing 1% arginine held at 25 \u00b0C and 33 \u00b0C showed improved stability compared to those using SPG buffer alone.",
            "startOffset": 36929,
            "title": "Results"
        },
        {
            "endOffset": 34108,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "All formulations were held in glass vials (West Pharmaceutical Services, Exton, PA) containing 1 mL for stability testing at 2\u20138 \u00b0C, 25 \u00b0C, and 33 \u00b0C.",
            "startOffset": 33958,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 43051,
            "parents": [],
            "refoffsets": {
                "bib0465": {
                    "endOffset": 43050,
                    "startOffset": 43046
                }
            },
            "secId": "sec0035",
            "sentence": "l-Arginine may aid protein refolding, solubilization, the prevention of aggregation, and the prevention of nonspecific adsorption [43].",
            "startOffset": 42916,
            "title": "Discussion"
        },
        {
            "endOffset": 37824,
            "parents": [],
            "secId": "sec0030",
            "sentence": "During the validation stage, LAIV type B (B/Brisbane/60/2008) was formulated with the lead formulation containing 1% arginine (Formulation-09), and the use of SPG buffer alone (Formulation-01) was evaluated for comparison.",
            "startOffset": 37602,
            "title": "Results"
        },
        {
            "endOffset": 43837,
            "parents": [],
            "secId": "sec0035",
            "sentence": "rHSA provided a minor improvement over formulations containing arginine alone\u2014an improvement observed most dramatically during freeze\u2013thaw and agitation experiments with type B.",
            "startOffset": 43660,
            "title": "Discussion"
        },
        {
            "endOffset": 30094,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Liquid LAIV formulation development at PATH included four steps: (1) screening potential excipients, (2) optimizing lead formulations, (3) validating lead formulations with an alternate influenza virus strain, and (4) confirming formulation stability with a higher titer of virus, agitation, and freeze\u2013thaw exposure.",
            "startOffset": 29777,
            "title": "Introduction"
        },
        {
            "endOffset": 41892,
            "parents": [],
            "secId": "sec0035",
            "sentence": "This formulation consists of SPG with 1% arginine and 0.5% rHSA.",
            "startOffset": 41828,
            "title": "Discussion"
        },
        {
            "endOffset": 32117,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "As the detection limit of the TCID50 assay is 2 \u00d7 103 log10 TCID50/mL, changes in titer of greater than 0.5 log10 loss are detectable by this assay.",
            "startOffset": 31969,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 45800,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Ongoing work with a manufacturer is evaluating the addition of 1 log of virus to the vaccine formulation.",
            "startOffset": 45695,
            "title": "Discussion"
        },
        {
            "endOffset": 27092,
            "parents": [],
            "refoffsets": {
                "bib0325": {
                    "endOffset": 27091,
                    "startOffset": 27084
                },
                "bib0330": {
                    "endOffset": 27091,
                    "startOffset": 27084
                },
                "bib0335": {
                    "endOffset": 27091,
                    "startOffset": 27084
                },
                "bib0340": {
                    "endOffset": 27091,
                    "startOffset": 27084
                },
                "bib0345": {
                    "endOffset": 27091,
                    "startOffset": 27084
                }
            },
            "secId": "sec0005",
            "sentence": "LAIVs are made by combining the HA and NA genes of the target strain into an influenza virus genome that has been attenuated by adaptation to growth in colder temperatures [15\u201319].",
            "startOffset": 26912,
            "title": "Introduction"
        },
        {
            "endOffset": 34284,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Initially, we performed accelerated stability temperature testing at 37 \u00b0C, but most formulations lost greater than 1 log10 within 3 days.",
            "startOffset": 34146,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 41513,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The addition of rHSA to formulations of H1N1 and type B LAIV at titers of 1 \u00d7 107 log10 TCID50/mL improved stability during freezing and agitation compared to formulations with 1% arginine alone and SPG buffer alone.",
            "startOffset": 41297,
            "title": "Results"
        },
        {
            "endOffset": 35339,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "A p-value <0.05 was considered significant.",
            "startOffset": 35296,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 42915,
            "parents": [],
            "refoffsets": {
                "bib0465": {
                    "endOffset": 42914,
                    "startOffset": 42901
                },
                "bib0480": {
                    "endOffset": 42914,
                    "startOffset": 42901
                },
                "bib0490": {
                    "endOffset": 42914,
                    "startOffset": 42901
                },
                "bib0495": {
                    "endOffset": 42914,
                    "startOffset": 42901
                }
            },
            "secId": "sec0035",
            "sentence": "l-Arginine improves stability in a range of applications, including antibodies, vaccine antigens, and fusion proteins [43,46,48,49].",
            "startOffset": 42783,
            "title": "Discussion"
        },
        {
            "endOffset": 41078,
            "parents": [],
            "secId": "sec0030",
            "sentence": "We also assessed the effects of agitation and freeze\u2013thaw to confirm stability.",
            "startOffset": 40999,
            "title": "Results"
        },
        {
            "endOffset": 41666,
            "parents": [],
            "secId": "sec0035",
            "sentence": "This work identified a stable liquid LAIV formulation for potential use in monovalent, trivalent, or quadrivalent seasonal influenza vaccines.",
            "startOffset": 41524,
            "title": "Discussion"
        },
        {
            "endOffset": 33604,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The following excipients were evaluated: sucrose (Macron, cat#7723-04), glutamate (Sigma, cat#49621), sorbitol (Spectrum, cat#S0219), gelatin (Sigma\u2013Aldrich, cat#G0262), bovine serum albumin (BSA) (Roche, cat#03117332001), arginine HCl (Sigma, cat#A4599), glycine (JT Baker, cat#0581-01), potassium phosphate monobasic (Macron, cat#7746-04), potassium phosphate dibasic (Sigma, cat#P3786), lactalbumin (Spectrum, cat#L3065), hydroxypropyl methylcellulose (HPMC) (Sigma, cat#423238), polyvinylpyrrolidone (PVP) (BASF Kollidon 17PF), recombinant human serum albumin (rHSA) (Novozymes), and human serum albumin (HSA) (MP Biomedicals, LLC, cat# 0882351).",
            "startOffset": 32954,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 34475,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Formulations were tested as indicated in each experiment or until 1 log10 loss was observed.",
            "startOffset": 34383,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 39545,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Type B formulations with 1% arginine and 0.5% rHSA showed slightly improved stability compared to 1% arginine alone at 25 \u00b0C and 33 \u00b0C.",
            "startOffset": 39410,
            "title": "Results"
        },
        {
            "endOffset": 36184,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Arginine and BSA were selected as the best-performing excipients for further evaluation.",
            "startOffset": 36096,
            "title": "Results"
        },
        {
            "endOffset": 33710,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "All excipients were United States Pharmacopeia (USP) grade reagents or Generally Regarded as Safe (GRAS).",
            "startOffset": 33605,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 44648,
            "parents": [],
            "secId": "sec0035",
            "sentence": "HSA formulations could be revisited with a fatty-acid HSA reagent in future experiments.",
            "startOffset": 44560,
            "title": "Discussion"
        },
        {
            "endOffset": 25955,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Influenza viruses undergo constant antigenic drift and antigenic shift.",
            "startOffset": 25884,
            "title": "Introduction"
        },
        {
            "endOffset": 34571,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Each experiment involved triplicate testing of one vial of each formulation at each time point.",
            "startOffset": 34476,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 45694,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Although we had access to only two seasonal strains for our studies, the results demonstrate that both could be stabilized for an entire influenza season.",
            "startOffset": 45540,
            "title": "Discussion"
        },
        {
            "endOffset": 39777,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The addition of 0.5% rHSA appeared to slightly improve the stability of formulations for both LAIV H1N1 and type B strains compared to stability with 1% arginine alone, although these differences were not statistically significant.",
            "startOffset": 39546,
            "title": "Results"
        },
        {
            "endOffset": 32470,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Because this was a feasibility study, a 1 log loss threshold was selected, representing approximately 0.23 log10 TCID50/mL (variability of the TCID50 assay) plus a true loss of approximately 0.7 log10 TCID50/mL, giving approximately 1 log10 loss of initial virus titer.",
            "startOffset": 32201,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 43433,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Because formulations containing these polymers were less stable than formulations with buffer alone, they were removed from the final formulation experiments.",
            "startOffset": 43275,
            "title": "Discussion"
        },
        {
            "endOffset": 27219,
            "parents": [],
            "refoffsets": {
                "bib0330": {
                    "endOffset": 27218,
                    "startOffset": 27208
                },
                "bib0350": {
                    "endOffset": 27218,
                    "startOffset": 27208
                },
                "bib0355": {
                    "endOffset": 27218,
                    "startOffset": 27208
                }
            },
            "secId": "sec0005",
            "sentence": "Cold-adapted viruses are developed by continual passage of wild-type influenza virus in primary chick kidney cells [16,20,21].",
            "startOffset": 27093,
            "title": "Introduction"
        },
        {
            "endOffset": 31320,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Plates were incubated for 6 days at 33 \u00b0C with 5% CO2.",
            "startOffset": 31266,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 35616,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Because this was an initial feasibility experiment, only one vial of each formulation was tested in triplicate in each experiment, limiting the performed statistical analyses.",
            "startOffset": 35441,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 35870,
            "parents": [],
            "secId": "sec0030",
            "sentence": "All formulations were stable at 2\u20138 \u00b0C for 6 weeks (Fig. 1A).",
            "startOffset": 35809,
            "title": "Results"
        },
        {
            "endOffset": 34888,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Freeze\u2013thaw was performed by freezing vials at \u221220 \u00b0C for 2 h and then thawing at 20\u201325 \u00b0C for 1 h, for three cycles.",
            "startOffset": 34771,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 25372,
            "parents": [],
            "refoffsets": {
                "bib0255": {
                    "endOffset": 25371,
                    "startOffset": 25368
                }
            },
            "secId": "sec0005",
            "sentence": "Seasonal influenza affects millions of people each year, causing morbidity, mortality, and economic loss [1].",
            "startOffset": 25263,
            "title": "Introduction"
        },
        {
            "endOffset": 45406,
            "parents": [],
            "secId": "sec0035",
            "sentence": "The role of viral genetic differences in formulation stability has not been investigated.",
            "startOffset": 45317,
            "title": "Discussion"
        },
        {
            "endOffset": 40999,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations with SPG, 1% arginine, and 0.5% rHSA at a titer of 1 \u00d7 107 log10 TCID50/mL showed a time to 1 log10 loss of 42.6 weeks and 3.3 weeks for H1N1 and 42.2 weeks and 3.8 weeks for type B at 2\u20138 \u00b0C and 25 \u00b0C, respectively.",
            "startOffset": 40770,
            "title": "Results"
        },
        {
            "endOffset": 35124,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0025",
            "sentence": "Data points at or below the limit of detection were excluded from the analysis.",
            "startOffset": 35045,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39940,
            "parents": [],
            "secId": "sec0030",
            "sentence": "By using the decay rate, we calculated the number of weeks to reach 1 log10 loss at 2\u20138 \u00b0C or 25 \u00b0C using the lower bound of the 95% confidence interval (Fig. 4D).",
            "startOffset": 39777,
            "title": "Results"
        },
        {
            "endOffset": 42674,
            "parents": [],
            "refoffsets": {
                "bib0435": {
                    "endOffset": 42673,
                    "startOffset": 42663
                },
                "bib0465": {
                    "endOffset": 42673,
                    "startOffset": 42663
                },
                "bib0470": {
                    "endOffset": 42673,
                    "startOffset": 42663
                },
                "bib0475": {
                    "endOffset": 42673,
                    "startOffset": 42663
                }
            },
            "secId": "sec0035",
            "sentence": "Amino acids use various mechanisms to stabilize formulations and are used with a variety of biomolecules [37,43\u201345].",
            "startOffset": 42558,
            "title": "Discussion"
        },
        {
            "endOffset": 34770,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Stability during agitation was evaluated by horizontally shaking vials containing formulations for 24 h at 200 rpm at 20\u201325 \u00b0C.",
            "startOffset": 34643,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 39409,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Type B formulations with 1% arginine showed statistically significant improvements in stability compared to formulations with SPG buffer alone at 2\u20138 \u00b0C and 25 \u00b0C (p-values <0.0001).",
            "startOffset": 39227,
            "title": "Results"
        },
        {
            "endOffset": 27979,
            "parents": [],
            "refoffsets": {
                "bib0360": {
                    "endOffset": 27978,
                    "startOffset": 27971
                },
                "bib0370": {
                    "endOffset": 27978,
                    "startOffset": 27971
                }
            },
            "secId": "sec0005",
            "sentence": "Its advantages over IIVs include simpler manufacturing, higher yield, faster release, and ease of use [22,24].",
            "startOffset": 27869,
            "title": "Introduction"
        },
        {
            "endOffset": 31056,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Cells were plated in 96-well plates (Nunc 167314) by adding 0.2 mL of 0.75 \u00d7 105 cells/mL to each well and incubated at 37 \u00b0C with 5% CO2 for 18\u201324 h. Plated cells were washed and maintained in serum-free Eagle's minimum essential medium (ATCC) containing 10 mg/mL tosyl-phenylalanyl-chlorophenyl ketone (TPCK)-treated trypsin (cat# TRTVMF, Worthington Biochemical Corporation).",
            "startOffset": 30678,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 44946,
            "parents": [],
            "secId": "sec0035",
            "sentence": "A liquid LAIV formulation allows for a vaccine that is easier to use, potentially leading to greater acceptance and wider adoption of seasonal vaccination.",
            "startOffset": 44791,
            "title": "Discussion"
        },
        {
            "endOffset": 32953,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "All formulations were within a pH range of 6.7\u20137.2 and an osmolarity range of 309\u2013522 mOsm.",
            "startOffset": 32862,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 41827,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Through several formulation stages and testing by TCID50, we identified a formulation with stability of 42 weeks at 2\u20138 \u00b0C for type A and type B influenza LAIV.",
            "startOffset": 41667,
            "title": "Discussion"
        },
        {
            "endOffset": 32776,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "Formulations were prepared as indicated in Table 1.",
            "startOffset": 32725,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 43562,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Future work needs to evaluate the potential benefits of adding these polymers to the stable formulation identified in this work.",
            "startOffset": 43434,
            "title": "Discussion"
        },
        {
            "endOffset": 44470,
            "parents": [],
            "secId": "sec0035",
            "sentence": "In addition, HSA formulations showed increased turbidity over time, which may have decreased stability.",
            "startOffset": 44367,
            "title": "Discussion"
        },
        {
            "endOffset": 44366,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Although BSA showed improved stability in the initial stages, we removed animal-derived products from our formulations and substituted rHSA because animal-derived reagents may cause faith-based concerns or concerns about possible contamination with endogenous diseases.",
            "startOffset": 44097,
            "title": "Discussion"
        },
        {
            "endOffset": 42335,
            "parents": [],
            "refoffsets": {
                "bib0435": {
                    "endOffset": 42274,
                    "startOffset": 42264
                },
                "bib0450": {
                    "endOffset": 42274,
                    "startOffset": 42264
                },
                "bib0455": {
                    "endOffset": 42274,
                    "startOffset": 42264
                }
            },
            "secId": "sec0035",
            "sentence": "Although sorbitol is a well-established osmolyte for stabilizing proteins and preventing aggregation [37,40,41], it did not stabilize the LAIV strains tested in this study.",
            "startOffset": 42163,
            "title": "Discussion"
        },
        {
            "endOffset": 42557,
            "parents": [],
            "refoffsets": {
                "bib0435": {
                    "endOffset": 42556,
                    "startOffset": 42549
                },
                "bib0460": {
                    "endOffset": 42556,
                    "startOffset": 42549
                }
            },
            "secId": "sec0035",
            "sentence": "Because of their size and surface activity, they accumulate at the air-liquid interface, potentially shielding formulation components from surface tension [37,42].",
            "startOffset": 42394,
            "title": "Discussion"
        },
        {
            "endOffset": 26585,
            "parents": [],
            "secId": "sec0005",
            "sentence": "These are inactivated influenza vaccines (IIVs) and live attenuated, cold-adapted influenza virus vaccines (LAIVs).",
            "startOffset": 26470,
            "title": "Introduction"
        },
        {
            "endOffset": 27663,
            "parents": [],
            "refoffsets": {
                "bib0295": {
                    "endOffset": 27662,
                    "startOffset": 27659
                }
            },
            "secId": "sec0005",
            "sentence": "Moreover, a cell-mediated immune response similar to infection with wild influenza, may offer broader protection against strain variants [9].",
            "startOffset": 27522,
            "title": "Introduction"
        },
        {
            "endOffset": 42002,
            "parents": [],
            "refoffsets": {
                "bib0435": {
                    "endOffset": 42001,
                    "startOffset": 41994
                },
                "bib0440": {
                    "endOffset": 42001,
                    "startOffset": 41994
                }
            },
            "secId": "sec0035",
            "sentence": "Formulation stability of LAIV is influenced by several factors (e.g., strain, pH buffer, aggregation) [37,38].",
            "startOffset": 41892,
            "title": "Discussion"
        },
        {
            "endOffset": 32724,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0020",
            "sentence": "The starting materials, monovalent bulk influenza vaccines H1N1 (A/California/07/2009) and type B (B/Brisbane/60/2008), were provided by SIIL in sucrose phosphate glutamate (SPG) buffer at a concentration of 2 \u00d7 107 log10 TCID50/mL.",
            "startOffset": 32492,
            "title": "Vaccine formulation"
        },
        {
            "endOffset": 38619,
            "parents": [],
            "secId": "sec0030",
            "sentence": "In addition, to avoid using animal-derived raw materials, we tested formulations that substituted HSA or rHSA for BSA.",
            "startOffset": 38501,
            "title": "Results"
        },
        {
            "endOffset": 32200,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "LAIV formulation stability was defined as the time to 1 log10 loss of virus titer.",
            "startOffset": 32118,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 31968,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Live virus titers determined by the TCID50 assay were compared to those determined with the 50% Egg Infectious Dose (EID50) assay (the SIIL potency release assay) and found to be approximately 0.5 log10 lower.",
            "startOffset": 31759,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 37984,
            "parents": [],
            "secId": "sec0030",
            "sentence": "LAIV formulations with 1% arginine with H1N1 were included to act as a bridge to previous formulation experiments (influenza titer of 2 \u00d7 106 log10 TCID50/mL).",
            "startOffset": 37825,
            "title": "Results"
        },
        {
            "endOffset": 26911,
            "parents": [],
            "refoffsets": {
                "bib0280": {
                    "endOffset": 26910,
                    "startOffset": 26899
                },
                "bib0295": {
                    "endOffset": 26910,
                    "startOffset": 26899
                },
                "bib0305": {
                    "endOffset": 26910,
                    "startOffset": 26899
                },
                "bib0310": {
                    "endOffset": 26910,
                    "startOffset": 26899
                },
                "bib0315": {
                    "endOffset": 26910,
                    "startOffset": 26899
                },
                "bib0320": {
                    "endOffset": 26910,
                    "startOffset": 26899
                }
            },
            "secId": "sec0005",
            "sentence": "Although millions of people have received split and subunit vaccines, these vaccines are less effective in young children [6,9,11\u201314].",
            "startOffset": 26777,
            "title": "Introduction"
        },
        {
            "endOffset": 38500,
            "parents": [],
            "secId": "sec0030",
            "sentence": "The higher titer better mimics what would be present in a vaccine product.",
            "startOffset": 38426,
            "title": "Results"
        },
        {
            "endOffset": 36095,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Sorbitol was the worst-performing excipient at 25 \u00b0C for both concentrations tested (Fig. 1B).",
            "startOffset": 36001,
            "title": "Results"
        },
        {
            "endOffset": 31475,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Assay performance was monitored by including a sample of LAIV (NASOVAC\u00ae) with each assay.",
            "startOffset": 31386,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 43143,
            "parents": [],
            "secId": "sec0035",
            "sentence": "In this study, l-arginine at 1% greatly increased the stability of the LAIV strains tested.",
            "startOffset": 43052,
            "title": "Discussion"
        },
        {
            "endOffset": 30171,
            "parents": [],
            "secId": "sec0005",
            "sentence": "This process produced a liquid LAIV formulation stable for 1 year at 2\u20138 \u00b0C.",
            "startOffset": 30095,
            "title": "Introduction"
        },
        {
            "endOffset": 44790,
            "parents": [],
            "secId": "sec0035",
            "sentence": "In conclusion, this paper describes the successful identification of stable liquid LAIV formulations for use in seasonal vaccination programs.",
            "startOffset": 44648,
            "title": "Discussion"
        },
        {
            "endOffset": 26175,
            "parents": [],
            "refoffsets": {
                "bib0265": {
                    "endOffset": 26174,
                    "startOffset": 26171
                }
            },
            "secId": "sec0005",
            "sentence": "Antigenic shift occurs when two influenza strains exchange genome segments in a process called reassortment, resulting in a new virus [3].",
            "startOffset": 26037,
            "title": "Introduction"
        },
        {
            "endOffset": 28852,
            "parents": [],
            "secId": "sec0005",
            "sentence": "To increase global vaccine supplies and support development of influenza vaccines in developing countries, the World Health Organization selected three developing-country manufacturers for a technology transfer initiative to strengthen capacity to produce LAIV against seasonal and pandemic influenza.",
            "startOffset": 28551,
            "title": "Introduction"
        },
        {
            "endOffset": 30677,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "In addition, the reagent PrestoBlue (Life Technologies A13262) was selected to determine cell viability after infection.",
            "startOffset": 30557,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 26469,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Two main types of vaccines are licensed to prevent seasonal influenza.",
            "startOffset": 26399,
            "title": "Introduction"
        },
        {
            "endOffset": 39116,
            "parents": [],
            "secId": "sec0030",
            "sentence": "H1N1 formulations with 1% arginine improved stability compared to formulations with SPG buffer alone (p-value <0.0001), but not as much as formulations containing 1% arginine with 0.5% rHSA (Formulation-20, p-value <0.0001) at 25 \u00b0C.",
            "startOffset": 38883,
            "title": "Results"
        },
        {
            "endOffset": 42162,
            "parents": [],
            "refoffsets": {
                "bib0365": {
                    "endOffset": 42161,
                    "startOffset": 42154
                },
                "bib0445": {
                    "endOffset": 42161,
                    "startOffset": 42154
                }
            },
            "secId": "sec0035",
            "sentence": "SPG is a commonly used stabilization buffer and is present in several widely used vaccines, such as measles, mumps, rubella (MMR) vaccine and FluMist\u00ae [23,39].",
            "startOffset": 42003,
            "title": "Discussion"
        },
        {
            "endOffset": 35808,
            "parents": [],
            "secId": "sec0030",
            "sentence": "In the first formulation stage, excipients were screened for their ability to improve the stability of LAIV compared to the vaccine in SPG buffer alone, as assessed by TCID50 (Fig. 1).",
            "startOffset": 35624,
            "title": "Results"
        },
        {
            "endOffset": 43274,
            "parents": [],
            "refoffsets": {
                "bib0500": {
                    "endOffset": 43273,
                    "startOffset": 43269
                }
            },
            "secId": "sec0035",
            "sentence": "The polymers PVP and HPMC were included because of their use in mucosal formulations and their potential stabilizing benefits [50].",
            "startOffset": 43143,
            "title": "Discussion"
        },
        {
            "endOffset": 31265,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "sec0015",
            "sentence": "Influenza virus was serially 10-fold diluted and MDCK cell monolayers were infected with influenza virus at dilutions of 10\u22122 to 10\u22128, with a total of six replicates per dilution and 0.2 mL inoculum per well.",
            "startOffset": 31057,
            "title": "Virus potency assay"
        },
        {
            "endOffset": 37514,
            "parents": [],
            "secId": "sec0030",
            "sentence": "A formulation containing 0.5% gelatin and 1% arginine showed stability similar to formulations of 1% arginine alone at 25 \u00b0C and 33 \u00b0C (Fig. 2B and C).",
            "startOffset": 37363,
            "title": "Results"
        },
        {
            "endOffset": 36627,
            "parents": [],
            "secId": "sec0030",
            "sentence": "As in the screening phase, arginine (Formulation-09) increased the stability of LAIV compared to SPG buffer alone (Formulation-01).",
            "startOffset": 36496,
            "title": "Results"
        },
        {
            "endOffset": 37233,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations containing 3% arginine held at 25 \u00b0C and 33 \u00b0C showed an improvement in stability similar to formulations containing 1% arginine when compared to SPG buffer alone.",
            "startOffset": 37057,
            "title": "Results"
        },
        {
            "endOffset": 38882,
            "parents": [],
            "secId": "sec0030",
            "sentence": "Formulations containing 1% arginine (Formulation-09) and 1% arginine with 0.5% rHSA (Formulation-20) with both H1N1 and type B were stable for the length of the experiment (42.6 weeks H1N1 and 42.2 weeks type B using the lower 95% confidence Interval) at 2\u20138 \u00b0C.",
            "startOffset": 38620,
            "title": "Results"
        },
        {
            "endOffset": 45196,
            "parents": [],
            "secId": "sec0035",
            "sentence": "The formulations identified in this work stabilized LAIV strains H1N1 (A/California/07/2009) and B (B/Brisbane/60/2008) for approximately one year (42 weeks using lower 95% confidence interval) at 2\u20138 \u00b0C and for up to approximately 4 weeks at 25 \u00b0C.",
            "startOffset": 44947,
            "title": "Discussion"
        },
        {
            "endOffset": 26308,
            "parents": [],
            "refoffsets": {
                "bib0275": {
                    "endOffset": 26307,
                    "startOffset": 26304
                }
            },
            "secId": "sec0005",
            "sentence": "Recommended influenza vaccines change each year due to frequent, rapid changes in antigenic determinants in circulating strains [5].",
            "startOffset": 26176,
            "title": "Introduction"
        },
        {
            "endOffset": 42393,
            "parents": [],
            "secId": "sec0035",
            "sentence": "Protein-based excipients are commonly used as stabilizers.",
            "startOffset": 42335,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X16302390",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "jawhite@path.org",
                "first": "Jessica A.",
                "initial": "J.A.",
                "last": "White"
            },
            {
                "email": null,
                "first": "Marcus",
                "initial": "M.",
                "last": "Estrada"
            },
            {
                "email": null,
                "first": "E. Alexander",
                "initial": "E.A.",
                "last": "Flood"
            },
            {
                "email": null,
                "first": "Kutub",
                "initial": "K.",
                "last": "Mahmood"
            },
            {
                "email": null,
                "first": "Rajeev",
                "initial": "R.",
                "last": "Dhere"
            },
            {
                "email": null,
                "first": "Dexiang",
                "initial": "D.",
                "last": "Chen"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.04.074",
        "firstpage": "3676",
        "issn": "0264410X",
        "keywords": [
            "Influenza vaccine",
            "Vaccine stabilization"
        ],
        "lastpage": "3683",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Development of a stable liquid formulation of live attenuated influenza vaccine"
    }
}